Alterskorrigierter Hörverlust nach Radiochemotherapie bei Patientinnen mit Zervixkarzinom

Marnitz, Simone; Schermeyer, Leon; Dommerich, Steffen; Køhler, Christer; Budach, Volker; Martus, Peter

doi:10.1007/s00066-018-1347-6

Cited by 13 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In terms of hearing perception alteration, the current results of the study show that less than half of patients worry about altered hearing perception, which is consistent with (Marnitz et al, 2018) and (Noszek et al, 2017) The current findings agree with Monfort et al, (2017) that cancer patients who receive ACH often experience falls and unstable gait. In addition, the research of Espy, Yang, Bhatt, & Pai, (2010) who showed that cancer patients often experience walking problems, feeling shaky, and having a decreased sense of balance, possibly affecting their ability to perform daily living tasks.…”

Section: Discussionsupporting

confidence: 91%

Assessment of sensory perception alterations for patients receiving Antineoplastic chemotherapy

Ahmed

2020

Port Said Scientific Journal of Nursing

View full text Add to dashboard Cite

Background: Alteration in sensory perception that occurs during anti neoplastic chemotherapy can seriously affect the health and nutritional status of patients, everyday life activities and recovery possibilities. Aim: This study aimed to assessment of sensory perception alteration for patients receiving anti neoplastic chemotherapy. Subjects and method: Across section study design using a mixed-methods study combining qualitative and quantitative approaches of data collection was adapted. A convenient sample from patients receiving anti neoplastic chemotherapy that were available within 6 months.The present study included a group of 100 Cancer patients receiving ACH. Data were collected through Sensory administrated questionnaire for quantitative data and interview schedule for qualitative data collection. Results: The majority of the patients in the study displayed alteration of taste perception reported the highest mean value (66.35) followed by sense of tactile perception alteration (57.54) then visual perception alteration(45.41) followed by hearing perception alteration (39.81) then sense of position perception alteration(37.97) and finally was sense of smell perception alteration (34.61) ,there are statistically significant relation between sense of vision and sense of tactile perception alteration with the starting date of ACH at p value ˂ 0.05. Also, six themes were identified in the current study which reported that more than half of patients express taste perception alterations. Recommendations:conducting educational programs to improve patient's knowledge and a wariness regarding receiving of ACH. Conclusion: Sensory perception alterations during ACH are significant complaints of cancer patients. In addition to reducing life satisfaction, poor compliance and even decreased response to therapy.

show abstract

Section: Discussionsupporting

confidence: 91%

Assessment of sensory perception alterations for patients receiving Antineoplastic chemotherapy

Ahmed

2020

Port Said Scientific Journal of Nursing

View full text Add to dashboard Cite

show abstract

“…Cisplatin is one of the most widely used anticancer drugs in the treatment of a variety of malignant tumors. It is also the most ototoxic drug in clinical use, causing permanent hearing loss in approximately 50% of treated patients [308][309][310][311][312]. A recent study showed that atorvastatin significantly reduced the incidence and severity of cisplatin-induced hearing loss [313].…”

Section: Maximizing Efficacy and Addressing Shortcomings Of Conventional Cancer Therapymentioning

confidence: 99%

Statins: a repurposed drug to fight cancer

Jiang

et al. 2021

J Exp Clin Cancer Res

197

142

View full text Add to dashboard Cite

As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subtypes of cancer are more vulnerable to statin therapy than others. Whether statins have clinical anticancer effects is still an active area of research. Statins appear to enhance the efficacy and address the shortcomings associated with conventional cancer treatments, suggesting that statins should be considered in the context of combined therapies for cancer. Here, we present a comprehensive review of the potential of statins in anti-cancer treatments. We discuss the current understanding of the mechanisms underlying the anti-cancer properties of statins and their effects on different malignancies. We also provide recommendations for the design of future well-designed clinical trials of the anti-cancer efficacy of statins.

show abstract

“…Many individuals treated with cisplatin experience significant toxicities, including nephrotoxicity, neurotoxicity, myelosuppression, and ototoxicity. Over 50% of patients who undergo cisplatin therapy acquire a sensorineural hearing loss (3)(4)(5)(6)(7), which compromises daily communication with friends, family, and health care providers and can lead to loneliness, social isolation, and frustration (8). Cisplatin-induced hearing loss is permanent, and there are currently no FDA-approved therapies to reduce or prevent cisplatin ototoxicity.…”

Section: Introductionmentioning

confidence: 99%

Atorvastatin is associated with reduced cisplatin-induced hearing loss

Fernandez¹,

Allen²,

Campbell³

et al. 2021

Journal of Clinical Investigation

View full text Add to dashboard Cite

BACKGROUND.Cisplatin is widely used to treat adult and pediatric cancers. It is the most ototoxic drug in clinical use, resulting in permanent hearing loss in approximately 50% of treated patients. There is a major need for therapies that prevent cisplatin-induced hearing loss. Studies in mice suggest that concurrent use of statins reduces cisplatin-induced hearing loss. METHODS.We examined hearing thresholds from 277 adults treated with cisplatin for head and neck cancer. Pretreatment and posttreatment audiograms were collected within 90 days of initiation and completion of cisplatin therapy. The primary outcome measure was a change in hearing as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).RESULTS. Among patients on concurrent atorvastatin, 9.7% experienced a CTCAE grade 2 or higher cisplatin-induced hearing loss compared with 29.4% in nonstatin users (P < 0.0001). A mixed-effect model analysis showed that atorvastatin use was significantly associated with reduced cisplatin-induced hearing loss (P ≤ 0.01). An adjusted odds ratio (OR) analysis indicated that an atorvastatin user is 53% less likely to acquire a cisplatin-induced hearing loss than a nonstatin user (OR = 0.47; 95% CI, 0.30-0.78). Three-year survival rates were not different between atorvastatin users and nonstatin users (P > 0.05). CONCLUSIONS.Our data indicate that atorvastatin use is associated with reduced incidence and severity of cisplatin-induced hearing loss in adults being treated for head and neck cancer. TRIAL REGISTRATION. ClinicalTrials.gov identifier NCT03225157.

show abstract

Alterskorrigierter Hörverlust nach Radiochemotherapie bei Patientinnen mit Zervixkarzinom

Abstract: Chemoradiation with cumulative cisplatin doses up to 400 mg did not lead to significant impairment of objective or subjective hearing. For cervical cancer patients undergoing chemoradiation, standard audiometry is not indicated.

Cited by 13 publications

References 45 publications

Assessment of sensory perception alterations for patients receiving Antineoplastic chemotherapy

Assessment of sensory perception alterations for patients receiving Antineoplastic chemotherapy

Statins: a repurposed drug to fight cancer

Atorvastatin is associated with reduced cisplatin-induced hearing loss

Contact Info

Product

Resources

About

Alterskorrigierter Hörverlust nach Radiochemotherapie bei Patientinnen mit Zervixkarzinom

Abstract: Chemoradiation with cumulative cisplatin doses up to 400 mg did not lead to significant impairment of objective or subjective hearing. For cervical cancer patients undergoing chemoradiation, standard audiometry is not indicated.

Cited by 13 publications

References 45 publications

Assessment of sensory perception alterations for patients receiving Antineoplastic chemotherapy

Assessment of sensory perception alterations for patients receiving Antineoplastic chemotherapy

Statins: a repurposed drug to fight cancer

Atorvastatin is associated with reduced cisplatin-induced hearing loss

Contact Info

Product

Resources

About

Abstract: Chemoradiation with cumulative cisplatin doses up to 400 mg did not lead to significant impairment of objective or subjective hearing. For cervical cancer patients undergoing chemoradiation, standard audiometry is not indicated.